Naturally circulating dendritic cells to vaccinate cancer patients

Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step...

Descripción completa

Detalles Bibliográficos
Autores principales: Bol, Kalijn F., Tel, Jurjen, de Vries, I. Jolanda M., Figdor, Carl G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661171/
https://www.ncbi.nlm.nih.gov/pubmed/23802086
http://dx.doi.org/10.4161/onci.23431
_version_ 1782270640698425344
author Bol, Kalijn F.
Tel, Jurjen
de Vries, I. Jolanda M.
Figdor, Carl G.
author_facet Bol, Kalijn F.
Tel, Jurjen
de Vries, I. Jolanda M.
Figdor, Carl G.
author_sort Bol, Kalijn F.
collection PubMed
description Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits.
format Online
Article
Text
id pubmed-3661171
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36611712013-06-25 Naturally circulating dendritic cells to vaccinate cancer patients Bol, Kalijn F. Tel, Jurjen de Vries, I. Jolanda M. Figdor, Carl G. Oncoimmunology Author's View Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits. Landes Bioscience 2013-03-01 2013-03-01 /pmc/articles/PMC3661171/ /pubmed/23802086 http://dx.doi.org/10.4161/onci.23431 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Bol, Kalijn F.
Tel, Jurjen
de Vries, I. Jolanda M.
Figdor, Carl G.
Naturally circulating dendritic cells to vaccinate cancer patients
title Naturally circulating dendritic cells to vaccinate cancer patients
title_full Naturally circulating dendritic cells to vaccinate cancer patients
title_fullStr Naturally circulating dendritic cells to vaccinate cancer patients
title_full_unstemmed Naturally circulating dendritic cells to vaccinate cancer patients
title_short Naturally circulating dendritic cells to vaccinate cancer patients
title_sort naturally circulating dendritic cells to vaccinate cancer patients
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661171/
https://www.ncbi.nlm.nih.gov/pubmed/23802086
http://dx.doi.org/10.4161/onci.23431
work_keys_str_mv AT bolkalijnf naturallycirculatingdendriticcellstovaccinatecancerpatients
AT teljurjen naturallycirculatingdendriticcellstovaccinatecancerpatients
AT devriesijolandam naturallycirculatingdendriticcellstovaccinatecancerpatients
AT figdorcarlg naturallycirculatingdendriticcellstovaccinatecancerpatients

Ejemplares similares